Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.25 SEK | -8.48% | -22.35% | +36.67% |
Sales 2023 | 5.68M 519K | Sales 2024 * | 23.65M 2.16M | Capitalization | 532M 48.6M |
---|---|---|---|---|---|
Net income 2023 | -178M -16.27M | Net income 2024 * | -155M -14.17M | EV / Sales 2023 | 48.9 x |
Net cash position 2023 | 111M 10.17M | Net Debt 2024 * | 25.35M 2.32M | EV / Sales 2024 * | 23.6 x |
P/E ratio 2023 |
-2.19
x | P/E ratio 2024 * |
-2.78
x | Employees | 31 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 57.48% |
Latest transcript on IRLAB Therapeutics AB
1 day | -8.48% | ||
1 week | -22.35% | ||
Current month | -34.29% | ||
1 month | -38.81% | ||
3 months | -29.31% | ||
6 months | +43.16% | ||
Current year | +36.67% |
Managers | Title | Age | Since |
---|---|---|---|
Clas Sonesson
FOU | Founder | 63 | 12-12-31 |
Chief Executive Officer | 71 | 17-05-05 | |
Nicholas Waters
FOU | Founder | 62 | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jan Anders Vedin
BRD | Director/Board Member | 82 | 15-12-31 |
Rein Piir
BRD | Director/Board Member | 66 | 15-12-31 |
Chairman | 66 | 19-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 10.25 | -8.48% | 53,070 |
24-04-25 | 11.2 | +6.16% | 40,046 |
24-04-24 | 10.55 | -8.26% | 107,324 |
24-04-23 | 11.5 | -7.26% | 37,691 |
24-04-22 | 12.4 | -6.06% | 58,486 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.67% | 48.49M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- IRLAB A Stock